

**ADVISORY BOARD  
Resolutions Update**

**American Academy of Dermatology Annual 2021 Resolutions**

**A. AAD001 (A-21): DataDerm Assistance for (Merit-Based Incentive Payment System) MIPS Compliance for Small Practices-on-Paper-Medical-Records**

**Proposed Motion:**

**RESOLVED**, the AADA/AAD incorporate within the DataDerm website a section for small practice-on-paper-medical-records; that access (icon, button, or link) is very visible on the DataDerm website, and that the existence of the site be publicized in DermWorld and/or other AAD communications; and be it further

**RESOLVED**, that within the small practice-on-paper-medical-records, a summary of small practice requirements for the relevant years is provided. In addition, potential viable solutions and worksheets to fulfill the various Improvement Activities (IA) and Quality Payment Program (QPP) measures should be available and downloadable. Furthermore, an example of the steps for the data entry into the registry should be included; and be it further

**RESOLVED**, that DataDerm have an embedded comment and Frequently Asked Questions (FAQ) section for the small practice-on-paper-medical-records in order to share feedback and ideas; and be it further

**RESOLVED**, that the DataDerm staff be commended for their support of the practicing dermatologists; and be it further

**RESOLVED**, that the Ad Hoc Task Force on Data Collection Platform and Clinical Registries create additional measures which may be easier to complete in small practice-on-paper-medical-records offices.

**Outcome:** The Board of Directors referred the resolution to the Performance Measurement Committee under the Council on Science and Research.

**Update:** The DataDerm Office Hours have given presentations on MIPS recommendations for paper-based practices, overviews on the Quality and Improvement Activity categories, and a MIPS submission demo. These presentations are available online as on-demand videos. Additionally, downloadable resources are available on the website and provide information on documentation tips and answers to frequently asked questions on each of the measures available in DataDerm.

**B. AAD002 (A-21): Videoconferencing for AAD/A Councils, Committees and Task Forces**

**Proposed Motion:**

**RESOLVED**, the AAD/A Board of Directors approve policy that mandates video conferencing software be used as the default method of communication for all AAD/A Councils, Committees and Task Forces' meetings that take place outside of in-person meetings; and be it further

**RESOLVED**, if audio-only conferencing must be used, then it is held over video conferencing software that includes participant tracking; and be it further

**RESOLVED**, the audio-only participants in a meeting identify themselves when they join the meeting.

**Outcome:** The Board of Directors adopted this resolution. The Governance Handbook will be updated to reflect this resolution.

**Update:** The Scientific Assembly Committee (SAC) will be developing virtual content in conjunction with the Annual Meeting and developing a robust digital strategy around future meeting content and digital education. The Committee will also pilot innovative methods of teaching with the next virtual meeting.

**C. AAD003 (A-21): Continue Virtual Meeting Presentations as an Alternative Attendance Option**

**Proposed Motion:**

**RESOLVED**, the AAD provide comprehensive online accessible content of the Annual and Summer Meetings with the ability to receive CME Credit as an environmentally friendly method to attend educational meetings.

**Outcome:** The Board of Directors referred this resolution to the Scientific Assembly Committee to perform a full assessment of all the educational options offered and the impact this resolution would have on them and the AAD.

**D. AAD004 (A-21): Focused Public Awareness Campaign regarding Advantages of Seeking Dermatologic Care from Board-Certified Dermatologists, rather than Independent Practice Nurse Practitioners ("aka" Doctors of Nursing Practice") or Physician Assistants**

**Proposed Motion:**

**RESOLVED**, that the AAD Board of Directors request the appropriate committee to allocate additional resources to develop an enhanced public relations, social media, and advertising campaign to educate the general public about the differences in the education and training of Fellows of the American Academy of Dermatology (FAAD) compared to independent nonphysician practitioners of dermatology.

**Outcome:** The Board of Directors referred this resolution to the Council on Communications. The Council on Communications is working to address this issue. More updates to come.

**E. AAD005 (A-21): Commitment to Free Speech and Open Debate**

**Proposed Motion:**

**RESOLVED**, that the AAD reaffirm its commitment to free speech, debate, and deliberation among all members and committees of the Academy; and be it further

**RESOLVED**, the AAD has a responsibility not only to promote freedom of debate and deliberation, but also to protect that freedom when others attempt to restrict it.

**Outcome:** The Board of Directors referred this resolution to the Professionalism and Ethics Committee for evaluation. The Committee will research the Chicago principles from the University of Chicago for background materials to review.

**Update:** The Board approved the Professionalism and Ethics Committee's recommendation ***NOT TO ADOPT*** this resolution because

- a) the legal and ethical rationales for the resolution are not sound,
- b) the resolution undermines the Academy's ethical and professional standards relating to collegiality, civility, and professionalism, and
- c) the resolution puts the Academy out of line with other medical societies, like the American Medical Association.

#### **F. AAD/A002 (A-21): Off-Label Use of Therapy Policy**

**Proposed Motion:**

**RESOLVED**, the AADA confirms and reaffirms its strong support for the autonomous clinical decision-making authority of a physician and that a physician may justifiably and lawfully use an FDA approved drug product or medical device for an off-label indication when such use is based upon sound scientific evidence and/or sound medical opinion; and be it further

**RESOLVED**, that the AADA opposes restriction by pharmacists and insurance carriers of "off-label" prescribing of medications, if the prescription of a drug or use of a device is accepted practice within the FAAD community to represent safe and effective therapy.

**Outcome:** The Board of Directors referred this resolution to the Drug Pricing and Transparency Task Force to draft a position statement to address off-label use of therapy.

#### **G. AAD/A004 (A-21): Political Commentary from AAD/A Leadership**

**Proposed Motion:**

**RESOLVED**, the Board of Directors as well as the elected officers of the American Academy of Dermatology Association in their official capacities should refrain from engaging in political commentary that does not directly pertain to the mission of the Academy.

**Outcome:** The Board of Directors rejected this resolution.

## **American Academy of Dermatology Summer 2021 Resolutions**

### **H. AAD001 (S-21): American Academy of Dermatology's Professionalism and Ethics Pledge**

**Proposed Motion:**

**RESOLVED**, that the American Academy of Dermatology remove the Professionalism and Ethics Pledge, as it is not directly related to and not a necessary part of the ethical practice of medicine.

**Outcome:** The Board of Directors referred this resolution to the Professionalism and Ethics.

### **I. AAD003 (S-21): American Board of Dermatology's Code of Conduct**

**Proposed Motion:**

**RESOLVED**, that the AAD oppose the creation of a Code of Conduct by the American Board of Dermatology, beyond that presently included in Section 3 of the Bylaws of the American Board of Dermatology, that may adversely affect AAD members.

**Outcome:** After discussion at the November Board of Directors' meeting, Andrew Weinstein, MD, FAAD, Advisory Board Chair, withdrew the resolution from consideration at this time to collect additional supporting materials for this and reintroduce at a later date.

### **J. AAD/A005 (S-21): Opening Opportunities for all Dermatologists – No More Closed Panels**

**Proposed Motion:**

**RESOLVED**, that the Advisory Board commends the American Academy of Dermatology Association (AAD/A) on its private payer advocacy with insurance companies; and be it Further

**RESOLVED**, that the AAD/A redouble their efforts to support and advocate for the private practice of dermatology through fair reimbursement rates and inclusive panels regardless of practice type, because divergent payments and closed panels continue to exist, for new dermatologists.

**Outcome:** The Board of Directors adopted this resolution.